Navigation Links
Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Date:5/14/2008

ISELIN, N.J., May 14 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) announced today that its President and Chief Financial Officer, S. Colin Neill, will present at the Rodman & Renshaw 5th Annual Global Healthcare Conference on Monday, May 19, 2008 at 5:15 PM Central Europe Daylight Time (GMT +2:00, or 11:15 AM Eastern Daylight Time). The conference is taking place May 19-20, 2008 at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.

In the presentation, Mr. Neill will provide an update on the Company's business and product pipeline. A webcast of the presentation will be available and archived for 90 days after the conference at http://www.wsw.com/webcast/rrshq13/pars. For additional information on this conference please visit http://www.rodmanandrenshaw.com/conferences?id=18.

About Pharmos Corporation

Pharmos Corporation is a biopharmaceutical company that discovers and develops novel therapeutics to treat a range of diseases of the nervous system, including disorders of the brain-gut axis, with a focus on pain/inflammation and autoimmune disorders. The Company's lead product, dextofisopam, is being studied in a Phase 2b clinical trial in patients with IBS. Dextofisopam has completed a Phase 2a IBS study in which it demonstrated a statistically significant effect compared to placebo on the primary efficacy endpoint of adequate relief (n=141, p=0.033) and was very well tolerated. A second program in Phase 2a involves a clinical trial of our NanoEmulsion cream drug delivery system to deliver the NSAID diclofenac topically in patients suffering from osteoarthr
'/>"/>

SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Pharmos Issues Letter to Shareholders
2. Pharmos Corporation Reports 2007 Third Quarter Results
3. Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
4. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
5. Pharmos Corporation Announces Board and Management Changes
6. Pharmos Corporation Completes Initial Closing of Private Placement
7. Pharmos Corporation Reports 2008 First Quarter Results
8. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... , CAMBRIDGE, Mass., Dec. 1 /PRNewswire/ -...y industry and to promote its potential, a group o...n of the Synthetic Biology Industry Association (S...goal of the association is to provide a forum for ...e new industry, address its opportunities and its ...
(Date:12/1/2009)... , SARASOTA, Fla., Dec. 1 Expan...prey Biotechnics Inc. of Sarasota has appointed La...tor. ,, Lake is located near Birmingham, Engla...acteria which serve the agricultural, waste water,...to be hungry and to open drain fields, and clean u...
(Date:12/1/2009)... Enterprise level storage is now ...oviders without breaking the bank. , ... LLC. ( www.pacsdrive.com ), a medical imaging s...COM compatible cloud storage service. The PacsDriv...re providers to securely archive medical imaging i...
(Date:12/1/2009)..., CRANBURY, N.J., Dec. 1 /PRNewswire-FirstCall/ ...oday announced that the U.S. Patent and Trademark ...d "Cyclic Natriuretic Peptide Constructs." The cl... compounds that bind to natriuretic peptide recept...rt failure drug candidate. ,, "Our natriuretic ...
Breaking Biology Technology:Industry Forms Association to Address Opportunities and Challenges of Synthetic Biology 2PacsDrive Announces Low Cost Medical Imaging Storage Service, Seeks to Alter Status Quo in Health Care IT 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 3
...s,(Nasdaq: DCGN ) today announced that its CLIA-r... which processes the company,s deCODEme(TM) person...ts for several common,diseases, has been accredite...llowing a recent inspection. The U.S. Centers for ...he CAP Laboratory Accreditation Program deeming,au...
...echnologies Inc. (IVT), a vaccine development comp...the National Research Council Institute for Biodia...ll develop new 3-D MRI technology to track the eff...mour growth. , "This research has the potential to... the individual cell level, and we will see, for t...
...c. (OTC Bulletin Board: SNBP) ("Sinobiopharma" or,... the Company,s progress to date this year and guid...e balance of 2009. , , Financial Highlights: , , ...e increased to RMB 4.60 million (US $0.68 million)...ar from the same period in 2008, when total sales ...
Other Biology Technology:deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 2deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 3deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 4ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imagin 2Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009 2Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009 3
(Date:12/1/2009)...he scientists, one from the United States, the oth..., the leader of his wolf pack, on remote Ellesmere... goal to finally find out what these "North Pole ... of the harshest areas of the world., "We first ...David Mech, a renowned U.S. Geological Survey (USG...
(Date:12/1/2009)...d first, a Monash University-led international res...t the output of the next generation of solar cells...ation with colleagues from the universities of Wol...ye-sensitised solar cells with a three-fold increa...reviously reported tandem dye-sensitised solar cel...
(Date:12/1/2009)...s aren,t just for listening to the radio anymore. ... devices. Research from North Carolina State Unive...gn creating shape-shifting antennas that open the... public safety to military deployment. , Modern ... there are limitations to how far they can be bent...
Breaking Biology News(10 mins):North Pole wolf emails locations to researchers 2North Pole wolf emails locations to researchers 3Innovation puts next-generation solar cells on the horizon 2Shape shifters: Researchers create new breed of antennas 2Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 12388 1Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 12388 2Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 12388 3Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 12388 4Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 12388 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 12388 6Laboratory Test May Predict Effectiveness of ERBITUX 28R 29 for Individual Colorectal Cancer Patients 12384 1Laboratory Test May Predict Effectiveness of ERBITUX 28R 29 for Individual Colorectal Cancer Patients 12384 2Laboratory Test May Predict Effectiveness of ERBITUX 28R 29 for Individual Colorectal Cancer Patients 12384 3Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 1Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 2Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 3Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 4Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 5
...c. 15, 2008] Three-quarters of youths with type 1...f vitamin D, according to a study by researchers a...t children with the disease may need vitamin D sup...fe. , "To our surprise, we found extremely high r....D., M.P.H., Chief of the Pediatric, Adolescent an...
...ve data from ESA,s Envisat satellite radar are bei...e track of the Vendee Globe solo round-the-world y...e Agency (CNES), acting through its new radar appl... Company), is using the race to demonstrate the ab...serve oceans at high resolution. ,Based on the tra...
...ars adapt to a warming Arctica frozen seascape tha...in an unlikely source: snow goose eggs. New calcul...breakup and of snow goose nesting near the western...s with an alternative source of food. This new ana...s, six subadult male bears were seen among snow go...
Other Biology News:Joslin research finds nearly three-quarters of youths with diabetes insufficient in vitamin D 2Vendee Globe route seen from above 2Goose eggs may help polar bears weather climate change 2
...he AquaMax DW4 liquid handling system from Molecul...h washing all in one instrument. The system handle...ate washing96-, 384- and 1536-welland is the first...W4 has been optimized to dispense from four differ...
...he Fluorescence Test Plate consists of an anodized...Organic Fluorescent Compounds embedded in polymeri...Lx800 and Synergy Multi-Detection Readers. This mu...nce while reducing the need for tedious wet testin...
...he DMW143 taken from the SMZ line is a Greenough s...s of production and testing. It is available with ...r a space-saving compact base (N2GG). This microsc...a projector all at the same time giving you ultima...
...ATra-si Reagent optimized for siRNA applications, ... be loaded with the nucleic acid of interest. Expl...s then rapidly drawn towards and delivered into th...MATra-si Reagent can be used for adherent cells; f...
Biology Products: